NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free STOK Stock Alerts $11.69 +0.03 (+0.26%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$11.11▼$11.8250-Day Range$5.27▼$14.1752-Week Range$3.35▼$16.40Volume564,531 shsAverage Volume1.24 million shsMarket Capitalization$609.28 millionP/E RatioN/ADividend YieldN/APrice Target$19.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Stoke Therapeutics alerts: Email Address Stoke Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside67.9% Upside$19.63 Price TargetShort InterestBearish10.61% of Shares Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.52Based on 7 Articles This WeekInsider TradingSelling Shares$41.98 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.28) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.23 out of 5 starsMedical Sector159th out of 908 stocksPharmaceutical Preparations Industry58th out of 423 stocks 4.4 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageStoke Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.61% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 11.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Stoke Therapeutics is -0.59. Previous Next 3.1 News and Social Media Coverage News SentimentStoke Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Stoke Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat Follows8 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,983,115.00 in company stock.Percentage Held by Insiders12.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.28) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Stoke Therapeutics Stock (NASDAQ:STOK)Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Read More STOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STOK Stock News HeadlinesApril 19, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in StockApril 2, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells $67,663.20 in StockApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 20, 2024 | americanbankingnews.comSkorpios Trust Sells 3,600,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) StockApril 19, 2024 | yahoo.comStoke-on-Trent to host its first comedy festivalApril 19, 2024 | msn.comStoke City predicted starting XI vs Plymouth as Steven Schumacher weighs up old boys' claimsApril 19, 2024 | msn.comProtest outside Stoke-on-Trent Crown Court - here's whyApril 17, 2024 | finance.yahoo.comStoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 17, 2024 | businesswire.comStoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerApril 17, 2024 | msn.comThe focus inside the Stoke City changing room ahead of Plymouth Argyle and 'biggest game of season'April 12, 2024 | benzinga.comStoke Therapeutics Stock (NASDAQ:STOK), Analyst Ratings, Price Targets, PredictionsApril 12, 2024 | markets.businessinsider.comBuy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market PositioningApril 4, 2024 | businesswire.comStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | markets.businessinsider.comAssessing Stoke Therapeutics: Insights From 6 Financial AnalystsApril 4, 2024 | seekingalpha.comStoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The WatchlistApril 3, 2024 | markets.businessinsider.comStrong Buy Rating for Stoke Therapeutics’ STK-001 Backed by Positive KOL Feedback and Revolutionary Potential in Dravet Syndrome TreatmentApril 1, 2024 | msn.comStoke Stock (NASDAQ:STOK) Gains on Drug Update; Is There More Upside Left?March 27, 2024 | businesswire.comStoke Therapeutics Announces Pricing of Upsized $125 Million Public OfferingMarch 27, 2024 | markets.businessinsider.comStoke Therapeutics’ STK-001 Shows Promise: Buy Rating Affirmed Amid Positive Clinical and Financial OutlookMarch 27, 2024 | marketwatch.comStoke Therapeutics Shares Extend Gains to 52-Week High, Plans for $75M OfferingMarch 27, 2024 | bizjournals.comStoke Therapeutics plans $75M public offering on heels of Dravet trial resultsMarch 27, 2024 | msn.comWhat's Going On With Stoke Therapeutics Stock Tuesday?March 27, 2024 | msn.comShares in Bedford-based Stoke Therapeutics surge after encouraging results in studies of epilepsy medicineMarch 26, 2024 | businesswire.comStoke Therapeutics Announces Proposed Public OfferingMarch 26, 2024 | msn.comTD Cowen ups Stoke to buy on updated data for epilepsy drugMarch 26, 2024 | msn.comStoke stock rockets 73% on updated epilepsy drug dataSee More Headlines Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today4/26/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$19.63 High Stock Price Target$35.00 Low Stock Price Target$12.00 Potential Upside/Downside+67.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,700,000.00 Net MarginsN/A Pretax Margin-1,192.47% Return on Equity-56.86% Return on Assets-41.59% Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.99 Sales & Book Value Annual Sales$8.78 million Price / Sales69.39 Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book3.27Miscellaneous Outstanding Shares52,120,000Free Float40,609,000Market Cap$609.28 million OptionableOptionable Beta0.77 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Edward M. Kaye M.D. (Age 75)Ph.D., CEO & Director Comp: $931.21kDr. Adrian R. Krainer Ph.D. (Age 65)Co-Founder & Independent Director Comp: $44kMr. Stephen J. Tulipano CPA (Age 65)MBA, Chief Financial Officer Comp: $619.09kDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Chief Medical Officer Comp: $688.83kMs. Isabel Aznarez Ph.D. (Age 51)Co-Founder & Group VP of Discovery Research Dr. Huw M. Nash Ph.D. (Age 57)COO & Chief Business Officer Comp: $429.67kMr. Eric RojasHead of Investor RelationsMr. Jonathan Allan J.D. (Age 34)Corporate Secretary & General Counsel Ms. Dawn Kalmar (Age 46)Chief Communications Officer Ms. Joan WoodChief Human Resources OfficerMore ExecutivesKey CompetitorsArriVent BioPharmaNASDAQ:AVBPAnaptysBioNASDAQ:ANABAstria TherapeuticsNASDAQ:ATXSPhathom PharmaceuticalsNASDAQ:PHATCOMPASS PathwaysNASDAQ:CMPSView All CompetitorsInsiders & InstitutionsSeven Grand Managers LLCBought 30,000 shares on 4/23/2024Ownership: 0.065%Skorpios TrustSold 3,600,000 sharesTotal: $41.76 M ($11.60/share)Jonathan AllanSold 5,126 sharesTotal: $67,663.20 ($13.20/share)Edward M Md KayeSold 11,150 sharesTotal: $68,015.00 ($6.10/share)Stephen J TulipanoSold 4,116 sharesTotal: $25,107.60 ($6.10/share)View All Insider TransactionsView All Institutional Transactions STOK Stock Analysis - Frequently Asked Questions Should I buy or sell Stoke Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" STOK shares. View STOK analyst ratings or view top-rated stocks. What is Stoke Therapeutics' stock price target for 2024? 9 analysts have issued 1-year target prices for Stoke Therapeutics' stock. Their STOK share price targets range from $12.00 to $35.00. On average, they predict the company's share price to reach $19.63 in the next twelve months. This suggests a possible upside of 67.9% from the stock's current price. View analysts price targets for STOK or view top-rated stocks among Wall Street analysts. How have STOK shares performed in 2024? Stoke Therapeutics' stock was trading at $5.26 at the beginning of 2024. Since then, STOK shares have increased by 122.2% and is now trading at $11.69. View the best growth stocks for 2024 here. Are investors shorting Stoke Therapeutics? Stoke Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,950,000 shares, an increase of 39.4% from the March 15th total of 3,550,000 shares. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is currently 4.9 days. Currently, 15.0% of the shares of the stock are sold short. View Stoke Therapeutics' Short Interest. When is Stoke Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our STOK earnings forecast. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its quarterly earnings results on Monday, March, 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.02. The firm had revenue of $2.80 million for the quarter, compared to analyst estimates of $3.70 million. What ETFs hold Stoke Therapeutics' stock? ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR).WisdomTree BioRevolution Fund (WDNA). What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA). When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Stoke Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Seven Grand Managers LLC (0.06%). Insiders that own company stock include Barry Ticho, Edward M Md Kaye, Huw M Nash, Jonathan Allan, Skorpios Trust and Stephen J Tulipano. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STOK) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
